Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: St. Jude

This article was originally published in The Gray Sheet

Executive Summary

St. Jude: St. Paul, Minnesota-based firm organizing tachycardia personnel and resources under the leadership of Mark Kroll, PhD, former VP Research and Product Planning at Minneapolis-based Angeion Corporation, who is appointed VP of the new St. Jude tachycardia division. St. Jude plans to form an advanced tachycardia research team in Minnesota to further its platform tachycardia technology; the firm holds rights to the technology through ongoing cross-patent and technology licensing agreements with Angeion. The firm also holds a worldwide distribution agreement to sell Angeion's Sentinel 2000 and 2001 implantable cardiac defibrillator models under a Pacesetter tradename. St. Jude expects the first implant of the ICD to occur in early 1996, according to an Oct. 31 release. In a separate release, Angeion reports that it received FDA approval to begin its own clinical trials in the U.S. for the Sentinel 2000 defibrillation system...

You may also be interested in...



EBITDA Margin Of 33% Not Sustainable, Krka Underlines

Krka’s bottom line continues to be stronger than usual, driven by a hike in sales and leaner cost base. Looking to 2021, however, management brought investors back down to earth.

Pandemic Spotlights Tensions Between Profit And Philanthropy

The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.

Pharma R&D’s COVID-19 Scar

Months of pandemic-induced disruption to health care systems and freedom of movement undoubtedly carries a cost. For the biopharmaceutical industry, this can be mitigated by its essential role in providing therapeutic interventions and leading the fightback via prophylactic vaccines. This softens the blow somewhat, certainly compared to other industries that are fully exposed to COVID-19 headwinds.

UsernamePublicRestriction

Register

OM006550

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel